Trial Profile
Investigation of Dual-HER2 Blockage Therapy in HER2-Positive Breast Cancer (exploratory randomized P-II)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Antihormones; Paclitaxel; Trastuzumab
- Indications Early breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Acronyms NeoLath
- 24 Aug 2018 Status changed from active, no longer recruiting to completed.
- 07 Jun 2016 Interim results of 222 tumor samples from 74 patients presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 27 Apr 2015 Planned End Date changed from 1 Sep 2018 to 31 Dec 2019 as reported by University Hospital Medical Information Network - Japan record.